This website uses cookies to give you the best user experience. If you continue without changing your settings we'll assume you are happy to receive all RSC cookies. You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions are also obtainable from the privacy link at the bottom of any RSC page.
Lite Version|Standard version
Home > RSC Advances >
To gain access to this content please
Log in via your home Institution.
Log in with your member or subscriber username and password.
Download


Buy PDF Add PDF to Basket (£42.50*)
*Exclusive of taxes
This article contains 3 page(s)
Abstract | Cited by

Co-delivery of anti-cancer agent Ellipticine (EPT) and Bcl-2 siRNA was mediated by a modified cell penetrating peptide, stearylated H16R8 (STR-H16R8). The stability and efficacy of the EPT nanoparticles was improved significantly by the amphiphilic peptide. Efficacy of STR-H16R8 stabilized EPT nanoparticles was further enhanced with Bcl-2 siRNA.

Graphical abstract: Co-delivery of drug nanoparticles and siRNA mediated by a modified cell penetrating peptide for inhibiting cancer cell proliferation

Page: ^ Top


Enter Keywords, author, title,reference, or DOI
Log in | Register